Celcuity
@celcuity
Followers
101
Following
0
Media
69
Statuses
78
Clinical-stage biotechnology company developing targeted therapies for cancer. Our lead compound, gedatolisib, is a potential first-in-class PI3K-mTOR inhibitor
Minneapolis, MN
Joined August 2022
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial.Webcast: PR: #teamcelcuity #oncology #biotechnology #data #phase3
0
3
11
#News: Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer on Monday, July 28, 2025, at 8:00 AM ET.PR Here: #teamcelcuity #oncology #biotechnology
0
2
3
#News: Today, Celcuity announced First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer.PR Here: #teamcelcuity #oncology #biotechnology
0
2
4
Our investigational drug candidate is a multi-target inhibitor of the PI3K/AKT/mTOR (PAM) pathway, one of the most important and frequently mutated cancer pathways. Learn more about our potential here:
celcuity.com
0
1
2
Celcuity’s commitment to delivering hope through innovation is underscored by our drive to unlock a new potential standard-of-care treatment option for patients with HR+/HER2- advanced/metastatic breast cancer.
1
1
1
#News: Today, Celcuity announced issuance of a new patent for Gedatolisib that extends patent exclusivity into 2042.PR Here: #oncology #patent #biotechnology
0
2
2
Since 2012, our team has pursued development of targeted cancer therapies with an unwavering focus on improving patient outcomes. Our lead drug candidate, gedatolisib, uniquely blockades the PI3K/AKT/mTOR (PAM) pathway to redefine treatment possibilities for cancer patients.
1
3
5
Celcuity reported early clinical data for geda: .- Ph 1 (plus darolutamide in men w/ metastatic castration resistant prostate cancer): 6mo rPFS 66%.- Ph 2 (plus trastuzumab-pkrb as 3L+ therapy in patients with HER2+ metastatic breast cancer): 43% ORR .
0
0
2
#News: Celcuity reports first quarter 2025 financials and provides recent updates: A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: #earnings #financialresults #oncology
0
0
0
#News: Celcuity schedules the release of first quarter 2025 financial results for Wednesday, May 14, 2025 at 4:30 PM ET: . A live webcast presentation can be accessed using this link: #oncology #financialresults #earnings
0
0
0
We presented overall survival (OS) data at the SABCS 2024 from our Phase 1b study evaluating gedatolisib in combination with palbociclib and endocrine therapy. Read more here: View our poster from SABCS 2024 here:
0
0
1
We expect 2025 to be a transformational year for Celcuity as we anticipate reporting several clinical data readouts throughout the year. Read more about our upcoming milestones in our fourth quarter earnings press release:
0
1
2
#News: Celcuity reports third quarter 2024 financials and provides recent updates: A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: #earnings #oncology #biotechnology
0
0
0
October is #BreastCancerAwarenessMonth. #Celcuity joins individuals globally to honor those affected by breast cancer. Our team remains committed to clinically developing our lead drug candidate, gedatolisib, a potential first-in-class targeted therapy to treat breast cancer.
0
0
0
Today is #NationalMammographyDay. We join others to raise awareness for #breastcancer and the important role mammograms play in the early detection of breast cancer.
0
0
0
On this #WorldCancerResearchDay, we recognize and celebrate the scientists working effortlessly to develop an effective treatment for patients battling cancer. At Celcuity, our researchers are clinically developing a first-in-class treatment targeting the PI3K /mTOR pathway.
0
0
0